Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume

Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 22,510,000 shares of APLS short. 19.42% of Apellis Pharmaceuticals' shares are currently sold short. Learn More on Apellis Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 11.0. Learn More on Apellis Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: GTS Securities LLC, Wolverine Trading LLC, Jefferies Financial Group Inc., Group One Trading LLC, D. E. Shaw & Co. Inc., Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Tudor Investment Corp ET AL, Boothbay Fund Management LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.42% of Apellis Pharmaceuticals' floating shares are currently sold short.

Apellis Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 22,510,000 shares, an increase of 16.6% from the previous total of 19,310,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

19.42% of Apellis Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apellis Pharmaceuticals: Ascendis Pharma A/S (11.84%), Qiagen (1.88%), Viatris Inc. (3.86%), Roivant Sciences Ltd. (10.28%), Lantheus Holdings, Inc. (9.67%), Revolution Medicines, Inc. (10.47%), BridgeBio Pharma, Inc. (15.15%), TG Therapeutics, Inc. (17.60%), Legend Biotech Co. (5.98%), Sarepta Therapeutics, Inc. (6.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks.

Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is March, 31 2025.